Overall Score

Revenue Growth

ARCT remains a development-stage biotech with no meaningful revenue base yet, so long-term growth depends on pipeline execution rather than current sales.

The current price-to-sales ratio of 12.28x implies the market is still assigning value to future commercialization potential.

Profitability

TTM margins remain deeply negative, with operating margin at -433.4% and net margin at -391.9%, indicating the business is still far from profitability.

Return on equity (-46.5%) and return on invested capital (-53.0%) remain materially negative, showing poor current capital efficiency.

Financial Health

Liquidity remains strong with a current ratio of 5.88x and cash ratio of 5.71x, supported by cash per share of $6.74.

Balance sheet leverage remains modest, with debt-to-equity at 0.13x and debt-to-assets at 0.10x.

Cash Flow

Operating cash flow and free cash flow remain negative, with free cash flow per share at -$2.57 and free cash flow yield at -25.0%.

Cash conversion remains weak despite a large negative cash conversion cycle, reflecting the company’s ongoing cash burn profile.

Growth Efficiency

R&D intensity remains very high at 362.1% of revenue, which is consistent with a pipeline-heavy biotech model but also underscores the lack of operating leverage.

Stock-based compensation is elevated at 88.7% of revenue, which continues to dilute growth efficiency.